Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2017 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced the
appointment of Karen Koski as Head of Strategy and Investor Relations. The newly
created position will report directly to Oxford Immunotec's Chief Executive
Officer, Dr. Peter Wrighton-Smith. Ms. Koski will join the company on June
21, 2017.
"We are very excited to add Karen to the Oxford Immunotec team. She is not only
extremely knowledgeable about the diagnostics and blood banking industries, but
very familiar with our story and long-term strategy," said Dr. Wrighton-Smith.
"Karen's professional experience and knowledge of our industry will be
invaluable as we execute on our strategic growth plans and work to maximize
shareholder value."
Ms. Koski joins the Company with a wealth of knowledge and experience in the
diagnostics industry. Most recently, Ms. Koski served as a Director and Senior
Equity Analyst at BTIG, LLC where she covered companies in the Medical
Technology, Life Sciences, and Diagnostics sectors. Prior to joining BTIG, Ms.
Koski worked as an Equity Research Associate at Lazard Capital Markets, where
she focused on the Medical Technology sector. Earlier in her career, Ms. Koski
served as a Medical Technologist at Brigham and Women's Hospital in Boston,
Mass., where she specialized in clinical hematology, clinical microbiology,
clinical chemistry, and blood banking. Ms. Koski holds a B.S. in Medical
Technology from the University of Vermont.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT®.TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. Also obtained through the acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-
SPOT.PRT test are pipeline products as part of the Company's fourth intended
product line focused on the transplantation market. In addition to these four
product lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.06.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 546287
Anzahl Zeichen: 4354
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
